NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 8.16 against a street estimate of 7.18 — a beat of 13.6%.
with an average price target of ₹2,156.29.
CONFIDENT Laurus Labs reported record Q2 revenue and profit, led by CDMO growth and affordable medicines. Peptide and oligo investments expand future capabilities, while management targets over 30% EBITDA margins. Q2 FY26 Domestic revenue was described as less than 20%; exports remain the majority. Developed-market filings and emerging-market registrations are expanding. Analysts focused heavily on peptide commercialization, capacity utilization, CapEx and sustainable margins. Management emphasized long-term program visibility but withheld customer-specific commitments and revenue details. 2026-10-29…
Full summary in the app.
| Holder | Stake |
|---|---|
| Mirae Asset Nifty India Manufacturing ETF | 4.02% |
| New World Fund Inc | 3.53% |
| Anukar Projects | 3.24% |
| Smallcap World Fund, Inc | 2.26% |
| Barclays Wealth Trustees India | 1.55% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 LAURUS LABS LIMITED – Q1 FY2027 RESULTS SUMMARY HEADLINE NUMBERS • Revenue: ₹2,026 crore in Q1 FY27, up 29% year-on-year and 12% quarter-on-quarter | 2026-07-24 |
| Quarterly results · Q1 FY27 LAURUS LABS LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS CONSOLIDATED (Quarter ended June 30, 2026) • Revenue from operations: ₹2,026.31 c | 2026-07-24 |
| Annual report FY2026 LAURUS LABS LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue FY 2025-26: ₹6,813 crore, up 23% year-over-year • EBITDA: ₹1 | 2026-06-08 |
| Q4 FY26 earnings call LAURUS LABS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Total Revenue FY26: INR 6,813 crores, growth of 23% YoY • Q4 FY26 Revenue: INR 1,812 crores | 2026-05-05 |
| Quarterly results · Q4 FY26 LAURUS LABS LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year FY2025-26 Revenue from Operations: ₹6,812.90 Cr (vs ₹5,553 | 2026-04-30 |
| Investor presentation LAURUS LABS LIMITED – FY2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Revenue FY26: ₹6,813 Cr, up 23% YoY (₹5,554 Cr in FY25) • Q4 FY26 Re | 2026-04-30 |
| Quarterly results | 2026-04-28 |
| Q3 FY26 earnings call LAURUS LABS LIMITED Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY'26 Revenue: Rs. 1,778 crores, growth of 26% year-on-year • 9-Month FY'26 Revenue: Rs. | 2026-01-28 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1 / share ex-date Nov 6, 2026 | 2026-11-06 |
| Dividend | ₹1.20 / share ex-date May 8, 2026 | 2026-05-08 |
| Dividend | ₹0.80 / share ex-date Oct 31, 2025 | 2025-10-31 |
| Announcement | Date |
|---|---|
| Acquisition of Galenvs Sciences announced alongside quarterly and half-year financial results Laurus Labs reported strong Q2 and H1 FY27 results for the period ended September 30, 2026. Q2 revenue rose 33% year-on-year to ₹2,206 crore, while EBITDA increased 78% to ₹762 crore. EBITDA | 2026-10-29 |
| Acquisition announced Laurus Labs’ board approved acquiring a 52% stake in SI & C Resins Private Limited (SI&C), making it a subsidiary. Laurus will invest ₹32.5 crore in cash by subscribing to 10,833 new shares, | 2026-10-29 |
| Update on acquisition Laurus Labs invested ₹107.8 crore in its joint venture KRKA Pharma through a rights issue, acquiring 10.78 crore shares at ₹10 each. After the investment, Laurus Labs holds 26.215 crore KRKA | 2026-10-14 |
| Update on acquisition announced Laurus Labs invested ₹12.10 crore in Kurnool Renewables Private Limited (KRPL) through a rights issue, acquiring 1,20,96,050 equity shares with a face value of ₹10 each. After the investment | 2026-10-06 |
| Update on acquisition of another business or strategic combination Laurus Labs Limited has informed the Exchange about Update on Acquisition | 2025-12-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Laurus Labs Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.